Description
Details
LDN193189 is a highly potent and selective BMP pathway inhibitor specifically targeting ALK2 (IC50 = 5 nM) and ALK3 (IC50 = 30 nM) receptors and only weakly inhibiting ALK4, ALK5, and ALK7. It functions primarily through prevention of Smad1, Smad5, and Smad8 phosphorylation. LDN193189 has been shown to promote differentiation of neural progenitor cells from human pluripotent stem cells. It has also been used in animal models to reduce ectopic ossification to treat fibrodysplasia ossificans progressive (FOP).
Details
Details
| Molecular Weight | 442.94 |
|---|---|
| Molecular Formula | C25H22N6.HCl |
| Chemical Name | 4-[6-(4-Piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline hydrochloride |
| CAS Number | 1062368-62-0 |
| PubChem Identifier | 54613581 |
| Purity | >99% by HPLC analysis |
| Alternative Names | LDN-193189 hydrochloride |
| Solubility | Soluble in DMSO at 50 mM and water at 30 mM |
| Reconstitution | For powder form, reconstitute in DMSO to the desired concentration. For detailed instructions on reconstitution and use in cell culture please reference technical data sheet. |
| Storage and Stability | Solid: Shipped at room temperature. Store at -20°C. Stable for 6 months when stored as directed. 10 mM Solution: Following reconstitution, store aliquots in tightly sealed vials at -20°C. Avoid repeated freeze-thaw cycles. |
| References | Chambers, S.M., et al. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27: 275-280. PMID: 19252484. Vogt, J., et al. (2011) The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell Signal 23: 1831-1842. PMID: 21740966. Yu, P.B., et al. (2011) BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14: 1363-1369. PMID: 19029982. |
| Technical Documents |